AstraZeneca Pharma disclosed on July 30, 2026, that it has received a demand notice from the National Pharmaceutical Pricing Authority (NPPA) for alleged overcharging under the Drugs (Prices Control) Order, 2013 (DPCO, 2013). The notice demands ₹148.66 crore, inclusive of interest, representing a significant potential financial liability stemming from pricing compliance issues dating back nearly a decade. This development follows a show cause notice issued by the regulator in September 2025, highlighting ongoing scrutiny of the company's pricing mechanisms for its respiratory drug portfolio.

The demand notice was received by the company on July 29, 2026, and relates specifically to the product Symbicort Turbuhaler 160/4.5 (Inhaler). The NPPA alleges that AstraZeneca Pharma India Limited overcharged customers for this medication during the period from May 2016 to November 2025. The total amount demanded includes principal dues plus interest calculated up to August 20, 2026. The regulator has stipulated that the payment must be made within 30 days from the receipt of the notice.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in accordance with SEBI Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Tanya Sanish, Company Secretary & Compliance Officer, signed the filing submitted to both the BSE Limited and the National Stock Exchange of India Limited.

What the Numbers Show

The magnitude of the demand—₹148.66 crore—underscores the cumulative impact of alleged pricing deviations over a nine-and-a-half-year period. The inclusion of interest calculated up to August 20, 2026, suggests that the financial burden will continue to grow if the matter is not resolved promptly. For a pharmaceutical company, such regulatory penalties can affect net profit margins and cash flow projections, particularly if the liability is recognized in the current fiscal year. The specific focus on Symbicort Turbuhaler indicates that the NPPA’s scrutiny may be concentrated on high-volume respiratory treatments, which are critical to the company’s domestic revenue stream.

The company stated it is currently evaluating the demand notice and appropriate legal actions. No immediate financial provision has been disclosed in this filing, leaving investors to assess the potential impact on future earnings. The outcome of this regulatory action could set a precedent for how pricing compliance disputes are resolved in the pharmaceutical sector under DPCO, 2013.

AstraZeneca Pharma India Limited has received a demand notice from the National Pharmaceutical Pricing Authority (NPPA) for an amount of ₹79,97,457, inclusive of interest calculated up to August 10, 2026. The regulator alleges that the company sold Betaloc-50 (Metoprolol 50 mg tablets) at a maximum retail price (MRP) higher than the ceiling price notified under the Drugs (Prices Control) Order, 2013 (DPCO, 2013). The notice demands recovery of the overcharged amount within 30 days from the date of receipt.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The company received the direction on July 27, 2026, and filed the compliance with the Bombay Stock Exchange and National Stock Exchange on July 28, 2026. Tanya Sanish, Company Secretary & Compliance Officer, signed the filing.

Allegations and Regulatory Context

The NPPA alleges that AstraZeneca Pharma India Ltd. did not implement the revised ceiling prices on stocks available in the market following two specific notifications: Notification S.O. 644(E) dated March 2, 2016, and Notification S.O. 1352(E) dated June 2, 2016. According to the authority, this failure resulted in overcharging during the period of June to July 2016. The demand includes the principal overcharged amount along with applicable interest.

Company Response

The company stated that it is currently reviewing the demand notice and will take appropriate steps in accordance with applicable law. No further details regarding the financial impact or legal strategy were disclosed in the filing. The matter relates to pricing compliance under DPCO, 2013, which mandates ceiling prices for scheduled drugs to ensure affordability.